3rd CPG on Management of Tuberculosis
Download
Report
Transcript 3rd CPG on Management of Tuberculosis
TREATMENT of TB
in ADULTS
by
Dr. Irfhan Ali Hyder Ali
1
LEARNING OBJECTIVES
• To update on treatment regimes &
modalities for PTB & EPTB
• To present evidence-based updates to
best suit TB management in Malaysia
• To emphasise on the importance of
proper treatment
2
INTRODUCTION
• Important to provide a standardised TB
regimen for all TB cases
• This section will cover all aspects of
treatment:
– Pulmonary TB (PTB)
• New cases
• Relapse cases
– Extrapulmonary TB (EPTB)
– Standard regimes & duration
3
AIM OF TREATMENT
• Cure & reduce transmission
• Risk of developing TB is determined:
– infectiousness of index case
– smear positive PTB; PTB with cavities; laryngeal TB
– nature & duration of contact
– immune status of contact
4
EDUCATION
a. Nature of disease
b. Necessity of strict adherence with prolonged
treatment
c. Risks of defaulting treatment
d. Side effects of medication
e. Risks of transmission & need for respiratory
hygiene as well as cough/sneeze etiquette
5
PULMONARY TUBERCULOSIS (PTB)
IN ADULTS
NEW CASES
• 6-month regimen consisting of 2 months of
EHRZ (2EHRZ) followed by 4 months of HR
(4HR) is recommended for newly-diagnosed
PTB.
7
RECOMMENDED ANTITB DRUGS
RECOMMENDED DOSES
DRUG
Daily
Dose (range)
in mg/kg
body weight
Isoniazid (H)
5 (4 - 6)
Rifampicin (R) 10 (8 - 12)
Pyrazinamide 25 (20 - 30)
(Z)
Ethambutol
15 (15 - 20)
(E)
Streptomycin 15 (12 - 18)
(S)
3X a week
Maximum in
mg
300
600
2000
Dose (range) Maximum in
in mg/kg
mg
body weight
10 (8 - 12)
900
10 (8 - 12)
600
35 (30 – 40)*
3000*
1600
30 (25 – 35)*
2400*
1000
15 (12 – 18)*
1500*
8
NEW CASES (cont.)
• Pyridoxine 10 - 50 mg daily needs to be added
if isoniazid is prescribed.
• *Daily treatment is the preferred regimen.
Adopted from WHO. Treatment of Tuberculosis Guidelines (4th Ed.), 2010
9
IMPORTANT POINTS
• Rifampicin
– should be used for the whole duration of treatment.
– NS difference in effectiveness & safety between rifampicin
& other antibiotics in the rifamycin group.
– whenever possible, rifampicin dosage should not be lower
than recommended dosage (10 - 12 mg/kg).
• Pyrazinamide beyond 2 months during the intensive
phase does not confer further advantage if the
organism is fully susceptible.
• Recurrence rate is low for both ethambutol-based
regimen & for streptomycin-based regimen.
10
TREATMENT OF NEW CASES
11
PREVIOUSLY TREATED TB
• New cases who have taken treatment for
more than one month & are currently smear
or culture positive again (i.e. failure, relapse or
return after default)
12
DEFINITION
Previously treated
Relapse
Treatment after
failure
Treatment after
default
Patient previously treated for TB including
relapse, failure & default cases .
A patient whose most recent treatment
outcome was “cured” or “treatment
completed”, & who is subsequently
diagnosed with bacteriologically positive TB
by sputum smear microscopy or culture.
A patient who has received Category I
treatment for TB & in whom treatment has
failed.
A patient who returns to treatment,
bacteriologically positive by sputum smear
microscopy or culture, following
interruption of treatment for 2 or more
consecutive months.
13
PREVIOUSLY TREATED TB
• Recommend: retreatment regimen containing firstline drugs 2HRZES/1HRZE/5HRE if country-specific
data show low or medium levels of MDR-TB in these
patients or if such data is not available.
• Drug sensitivity test (DST) must be done for patients.
When results become available, drug regimen should
be adjusted appropriately.
*This is WHO statement, no retrievable evidence
available.
14
TO START OR NOT?
• Interruption in intensive phase:
– If ≥14 days, to restart from beginning i.e. Day 1.
– If <14 days, to continue form last dose.
15
TO START OR NOT?
• Interruption in maintenance phase:
– If interruption occurs after patient receives 80% of total
planned doses, treatment may be stopped if sputum AFB
smear was negative at initial presentation. If sputum AFB
smear was positive, treatment should be continued to
achieve total number of doses.
– If total doses <80% & interruption lapse is ≥2 months,
restart treatment from beginning.
– If total doses is <80% & interruption lapse is <2 months,
continue treatment from date it stops to complete full
course.
16
TREATMENT OF
PREVIOUSLY TREATED TB
17
OPTIMAL DURATION
• Patients with sputum positive PTB should receive
antiTB drugs for a minimum duration of 6 months.
• Regimens with shorter duration of rifampicin are
associated with higher risk of failure, relapse &
acquired drug resistance.
• Even in patients with non-cavitary disease &
confirmed sputum culture, conversion at 2 months
fares poorer with a 4-month regimen compared to 6month regimen.
18
OPTIMAL DURATION
19
MAINTENANCE PHASE
• In new patients with PTB, WHO recommends daily
dosing throughout the course of antiTB treatment.
• However, a daily intensive phase followed by thrice
weekly maintenance phase is an option provided
that each dose is directly observed & patient has
improved clinically.
• A maintenance phase with twice weekly dosing is not
recommended.
20
MAINTENANCE PHASE
• There is no difference in treatment failure, relapse &
acquired drug resistance rates between daily &
different intermittent dosing regimens in the
maintenance phase.1, 2, 3
1Menzies
D et al., PLoS Med, 2009
HC et al., Cochrane, 2001
3Chang KC et al., Thorax, 2011
2Mwandumba
21
MAINTENANCE PHASE
22
FIXED-DOSE COMBINATION
(FDC) IN MALAYSIA
• Forecox-Trac Film Coated Tab: isoniazid, rifampicin,
ethambutol & pyrazinamide
• Rimactazid 300 Sugar Coated Tab: isoniazid, & rifampicin
• Rimcure 3-FDC Film Coated Tab: isoniazid, rifampicin &
pyrazinamide
• Akurit-Z Tab: isoniazid, rifampin (rifampicin) & pyrazinamide
• Akurit Tab: isoniazid & rifampin (rifampicin)
• Akurit-Z Kid Dispersible Tab: isoniazid, rifampin (rifampicin) &
pyrazinamide
• Akurit-4: ethambutol, isoniazid, rifampin (rifampicin) &
pyrazinamide
23
FDC IN MOH
• 4-Drug combination: isoniazid 75 mg,
rifampicin 150 mg, pyrazinamide 400 mg &
ethambutol 275 mg tablet
• 3-Drug combination: isoniazid 75 mg,
rifampicin 150 mg & pyrazinamide 400 mg
tablet
24
RECOMMENDED DOSES
• 30 - 37 kg body weight: 2 tablets daily
• 38 - 54 kg body weight: 3 tablets daily
• 55 - 70 kg body weight: 4 tablets daily
• More than 70 kg body weight: 5 tablets daily
25
EFFECTIVENESS
• FDCs compared to separate-drug regimens
significantly reduce risk of non-compliance by
17% & consequently improve effectiveness of
therapy.1
• In term of bioavailability, FDCs are proven to
be bioequivalent to separate-drugs
formulations at the same dose levels.2
1Bangalore
S et al., Am J Med, 2007
2Agrawal S et al., Int J Pharm, 2002
26
OTHER ADVANTAGES
• Smaller number of tablets to be ingested may
also encourage patient adherence.
• Prescription errors are likely to be less
frequent for FDCs due to easy adjustment of
dosage according to patient weight.
27
FDC
28
DIRECTLY OBSERVED
THERAPY (DOT)
• Direct observation of drug ingestion of the
DOTS component should not be the sole
emphasis in TB control programmes.
• It should not be a blanket approach; instead it
should be a process of negotiation & support,
incorporating patients’ characteristics &
choices.
29
DIRECTLY OBSERVED
THERAPY (DOT)
• Enhanced DOTS involving intensive contact
tracing & treating the contacts with TB can
reduce incidence of TB within a community
(p=0.04).1
1Cavalcante
SC et al., Int J Tuberc & Lung Dis. 2010
30
DOT
31
EXTRAPULMONARY TUBERCULOSIS
(EPTB) IN ADULTS
DURATION OF EPTB TREATMENT NICE RECOMMENDATION1
• Meningeal TB – 2 months S/EHRZ+10HR*
• Peripheral lymph node TB – should normally
be stopped after 6 months
• Bone & joint TB – 6 months
• Pericardial TB – 6 months
1National
Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice. Tuberculosis: clinical diagnosis and
management of tuberculosis, and measures for its prevention and control. 2011
33
DURATION OF EPTB TREATMENT WHO RECOMMENDATION1
• Regimen should contain 6 months of
rifampicin: 2HRZE/4HR*
• Duration of treatment for TB meningitis is 9 12 months &, bone & joint TB is 9 months
1World
Health Organization. Treatment of tuberculosis Guidelines. Fourth ed. 2010
34
MILIARY & DISSEMINATED TB
• There is no retrievable evidence on optimal
duration of treatment for disseminated TB &
miliary TB.
• There should be low threshold to suspect TB
meningitis in these groups of patients &
treatment duration should be prolonged
between 9 to 12 months.
35
OPTIMAL DURATION OF
EPTB TREATMENT
36
CORTICOSTEROIDS IN EPTB
• Corticosteroid therapy may benefit patients
with some forms of EPTB. However literature
on corticosteroids in various form of EPTB is
scant.
37
CORTICOSTEROIDS IN
EPTB TREATMENT
38
TB MENINGITIS
Severity
Grade I
disease
Regime
Week 1: IV dexamethasone sodium phosphate 0.3
mg/kg/day
Week 2: 0.2 mg/kg/day
Week 3: Oral dexamethasone 0.1 mg/kg/day
Week 4: Oral dexamethasone a total of 3 mg/day,
decreasing by 1 mg each week
Grade II & III
disease
Week 1: IV dexamethasone sodium phosphate 0.4
mg/kg/day
Week 2: 0.3 mg/kg/day
Week 3: 0.2 mg/kg/day
Week 4: 0.1 mg/kg/day, then oral dexamethasone
for 4 weeks, decreasing by 1 mg each week
Prasad K et al., Cochrane, 2008
39
TB PERICARDITIS
40
SURGERY IN PTB
• Diagnosis & obtaining tissue for culture & drug
sensitivity
• Management of TB complications
• Treatment of the disease itself where drug
therapy alone may be deemed insufficient to
achieve cure
41
SURGERY IN PTB
• While the advancement in surgical techniques
including video-assisted thoracoscopy
surgery/thoracotomy has reduced the surgical
mortality & morbidity, surgery for PTB is still
associated with significant complications due
to the presence of adhesions & scarring.
42
MAIN CHANGES IN CPG TB 2012
• Evidence-based
• Treatment after interruption explained in more detail
• Treatment regimes (maintenance) changed to daily
or 3X a week
• FDCs mentioned
• DOTS covered in more detail & done to suit
Malaysian context
• Duration of treatment for EPTB more concise
– Use of steroids recommended for TB meningitis &
pericarditis
43
TAKE HOME MESSAGES
• Adhere to standard regime
• Use correct doses & adequate duration
• Ensure compliance
• Treatment needs to be individualised
• Consult a doctor/physician with experience in
TB management when in doubt
44
THANK YOU
[email protected]
45